-
Je něco špatně v tomto záznamu ?
One-Month Dual Antiplatelet Therapy Reduces Major Bleeding Compared With Longer-Term Treatment Without Excess Stent Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
G. Bajraktari, I. Bytyçi, G. Abdyli, P. Ibrahimi, A. Bajraktari, R. Karahoda, S. Elezi, MY. Henein
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, metaanalýza, systematický přehled
NLK
ProQuest Central
od 2012-08-15 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2012-08-15 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2012-08-15 do Před 2 měsíci
- MeSH
- Aspirin aplikace a dávkování škodlivé účinky MeSH
- časové faktory MeSH
- duální protidestičková léčba * škodlivé účinky metody MeSH
- inhibitory agregace trombocytů * aplikace a dávkování škodlivé účinky MeSH
- koronární angioplastika * škodlivé účinky MeSH
- koronární trombóza prevence a kontrola epidemiologie MeSH
- krvácení * chemicky indukované epidemiologie MeSH
- lidé MeSH
- randomizované kontrolované studie jako téma MeSH
- stenty uvolňující léky * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
Dual antiplatelet therapy (DAPT) remains the gold standard in patients who underwent percutaneous coronary intervention (PCI). This meta-analysis aims to evaluate the clinical safety of 1-month DAPT followed by aspirin or a P2Y12 receptor inhibitor after PCI with drug-eluting stents (DES). We searched PubMed, MEDLINE, Embase, Scopus, Google Scholar, Cochrane Central Registry, and ClinicalTrials.gov databases and identified 5 randomized controlled trials with 29,831 patients who underwent PCI with DES and compared 1-month versus >1-month DAPT. The primary end point was major bleeding, and the co-primary end point was stent thrombosis. The secondary end point included all-cause mortality, cardiovascular death, myocardial infarction, stroke, and major adverse cardiovascular or cerebrovascular events. Compared with >1-month DAPT, the 1-month DAPT was associated with a lower rate of major bleeding (odds ratio [OR] 0.66, 95% confidence interval [CI] 0.45 to 0.97, p = 0.03, I2 = 71%), whereas stent thrombosis had a similar rate in both study groups (OR 1.08, 95% CI 0.81 to 1.44, p = 0.60, I2 = 0.0%). The study groups had similar risks for all-cause mortality (OR 0.89, 95% CI 0.77 to 1.04, p = 0.14, I2 = 0.0%), cardiovascular death (OR 0.84, 95% CI 0.59 to 1.19, p = 0.32, I2 = 0.0%), myocardial infarction (OR 1.04, 95% CI 0.89 to 1.21, p = 0.62, I2 = 0.0%), and stroke (OR 0.82, 95% CI 0.64 to 1.05, p = 0.11, I2 = 6%). The risk of major adverse cardiovascular or cerebrovascular events was lower (OR 0.86, 95% CI 0.76 to 0.97, p = 0.02, I2 = 25%) in the 1-month DAPT compared with >1-month DAPT. In conclusion, in patients who underwent PCI with DES, 1-month DAPT followed by aspirin or a P2Y12 receptor inhibitor reduced major bleeding with no risk of increased thrombotic risk compared with longer-term DAPT.
Clinic of Cardiology University Clinical Centre of Kosova Prishtina Kosovo
Department of Public Health and Clinical Medicine Umeå University Umeå Sweden
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018908
- 003
- CZ-PrNML
- 005
- 20241024111058.0
- 007
- ta
- 008
- 241015e20240717xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.amjcard.2024.07.010 $2 doi
- 035 __
- $a (PubMed)39029722
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bajraktari, Gani $u Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Clinic of Cardiology, University Clinical Centre of Kosova, Prishtina, Kosovo; Medical Faculty, University of Prishtina, Prishtina, Kosovo. Electronic address: gani.bajraktari@umu.se
- 245 10
- $a One-Month Dual Antiplatelet Therapy Reduces Major Bleeding Compared With Longer-Term Treatment Without Excess Stent Thrombosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials / $c G. Bajraktari, I. Bytyçi, G. Abdyli, P. Ibrahimi, A. Bajraktari, R. Karahoda, S. Elezi, MY. Henein
- 520 9_
- $a Dual antiplatelet therapy (DAPT) remains the gold standard in patients who underwent percutaneous coronary intervention (PCI). This meta-analysis aims to evaluate the clinical safety of 1-month DAPT followed by aspirin or a P2Y12 receptor inhibitor after PCI with drug-eluting stents (DES). We searched PubMed, MEDLINE, Embase, Scopus, Google Scholar, Cochrane Central Registry, and ClinicalTrials.gov databases and identified 5 randomized controlled trials with 29,831 patients who underwent PCI with DES and compared 1-month versus >1-month DAPT. The primary end point was major bleeding, and the co-primary end point was stent thrombosis. The secondary end point included all-cause mortality, cardiovascular death, myocardial infarction, stroke, and major adverse cardiovascular or cerebrovascular events. Compared with >1-month DAPT, the 1-month DAPT was associated with a lower rate of major bleeding (odds ratio [OR] 0.66, 95% confidence interval [CI] 0.45 to 0.97, p = 0.03, I2 = 71%), whereas stent thrombosis had a similar rate in both study groups (OR 1.08, 95% CI 0.81 to 1.44, p = 0.60, I2 = 0.0%). The study groups had similar risks for all-cause mortality (OR 0.89, 95% CI 0.77 to 1.04, p = 0.14, I2 = 0.0%), cardiovascular death (OR 0.84, 95% CI 0.59 to 1.19, p = 0.32, I2 = 0.0%), myocardial infarction (OR 1.04, 95% CI 0.89 to 1.21, p = 0.62, I2 = 0.0%), and stroke (OR 0.82, 95% CI 0.64 to 1.05, p = 0.11, I2 = 6%). The risk of major adverse cardiovascular or cerebrovascular events was lower (OR 0.86, 95% CI 0.76 to 0.97, p = 0.02, I2 = 25%) in the 1-month DAPT compared with >1-month DAPT. In conclusion, in patients who underwent PCI with DES, 1-month DAPT followed by aspirin or a P2Y12 receptor inhibitor reduced major bleeding with no risk of increased thrombotic risk compared with longer-term DAPT.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Aspirin $x aplikace a dávkování $x škodlivé účinky $7 D001241
- 650 _2
- $a koronární trombóza $x prevence a kontrola $x epidemiologie $7 D003328
- 650 12
- $a stenty uvolňující léky $x škodlivé účinky $7 D054855
- 650 12
- $a duální protidestičková léčba $x škodlivé účinky $x metody $7 D000080903
- 650 12
- $a krvácení $x chemicky indukované $x epidemiologie $7 D006470
- 650 12
- $a koronární angioplastika $x škodlivé účinky $7 D062645
- 650 12
- $a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $7 D010975
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Bytyçi, Ibadete $u Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Clinic of Cardiology, University Clinical Centre of Kosova, Prishtina, Kosovo; Medical Faculty, University of Prishtina, Prishtina, Kosovo
- 700 1_
- $a Abdyli, Genc $u Clinic of Cardiology, University Clinical Centre of Kosova, Prishtina, Kosovo; Medical Faculty, University of Prishtina, Prishtina, Kosovo
- 700 1_
- $a Ibrahimi, Pranvera $u Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Clinic of Cardiology, University Clinical Centre of Kosova, Prishtina, Kosovo
- 700 1_
- $a Bajraktari, Artan $u Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Clinic of Cardiology, University Clinical Centre of Kosova, Prishtina, Kosovo
- 700 1_
- $a Karahoda, Rona $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Prague, Czech Republic
- 700 1_
- $a Elezi, Shpend $u Clinic of Cardiology, University Clinical Centre of Kosova, Prishtina, Kosovo; Medical Faculty, University of Prishtina, Prishtina, Kosovo
- 700 1_
- $a Henein, Michael Y $u Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
- 773 0_
- $w MED00000236 $t The American journal of cardiology $x 1879-1913 $g Roč. 227 (20240717), s. 91-97
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39029722 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111052 $b ABA008
- 999 __
- $a ok $b bmc $g 2201641 $s 1230881
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 227 $c - $d 91-97 $e 20240717 $i 1879-1913 $m The American journal of cardiology $n Am J Cardiol $x MED00000236
- LZP __
- $a Pubmed-20241015
